Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma
Mené sur 343 patients atteints d'un carcinome à cellules rénales de stade métastatique (durée médiane de suivi : 12 mois), cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du tivozanib, seul ou en combinaison avec le nivolumab
Immune checkpoint inhibitors (ICIs), specifically programmed cell death 1 protein (PD-1) inhibitors in combination with additional ICIs or vascular endothelial growth factor receptor targeting tyrosine kinase inhibitors (VEGFR TKIs), have become the standard first-line treatment for patients with advanced or metastatic renal cell carcinoma. Although ICI-based combination treatments have markedly improved outcomes for patients with metastatic renal cell carcinoma, resistance to anti-PD-1-based therapies remains common. A critical question in the field is whether, after progression on anti-PD-1-based therapy, patients should be treated with a VEGFR TKI alone or a combination of TKI plus PD-1 blockade (ie, anti-PD-1 rechallenge).